Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $25.40.

A number of research firms have issued reports on GENB. Morgan Stanley boosted their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of Generate Biomedicines from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, HC Wainwright lifted their price target on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th.

Generate Biomedicines Stock Performance

Shares of GENB opened at $13.40 on Monday. Generate Biomedicines has a 12 month low of $11.00 and a 12 month high of $18.18. The stock’s fifty day moving average is $14.34. The company has a market cap of $1.72 billion and a P/E ratio of -12.52.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.